To compare outcomes in patients with Acute Myeloid Leukemia received Fludarabine-Busulfan with the addition of Thiotepa and Fludarabine and Busulfan based myeloablative regimen for allogeneic stem cell transplantation

Trial Profile

To compare outcomes in patients with Acute Myeloid Leukemia received Fludarabine-Busulfan with the addition of Thiotepa and Fludarabine and Busulfan based myeloablative regimen for allogeneic stem cell transplantation

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Fludarabine (Primary) ; Busulfan
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Jul 2017 New trial record
    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top